{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:07:24Z","timestamp":1788822444969,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Legal Med"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00414-025-03708-7","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:34:34Z","timestamp":1768808074000},"page":"1299-1311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing the influence of CYP2C9 and CYP2C19 genotypes on the metabolism of CBD-cannabis after controlled single and repetitive consumption"],"prefix":"10.1007","volume":"140","author":[{"given":"Janine","family":"Schulte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Potzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priska","family":"Frei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Mercer\u2011Chalmers\u2011Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Scheurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette E. Meyer zu","family":"Schwabedissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7933-2563","authenticated-orcid":false,"given":"Iris","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"3708_CR1","unstructured":"i.mail Offizin Pharmaceutical Care Research Group, Universit\u00e4t Basel. Arzneimittel und Fahrf\u00e4higkeit. 2015. Nr.16\/30.8.2015 3\u20136. http:\/\/www.imail-offizin.ch\/ (accessed 01.03.2025)"},{"key":"3708_CR2","unstructured":"Achermann St\u00fcrmer Y Drogen und Medikamente im Strassenverkehr. Bern: buf - Beratungsstelle f\u00fcr Unfallverh\u00fctung; bfu-Faktenblatt 2014. Nr. 10 (accessed 01.03.2025)"},{"key":"3708_CR3","unstructured":"von Herrath D, Ludwig WD, Schuler J Arzneimittel und Fahrt\u00fcchtigkeit im Strassenverkehr. Arzneimittelbrief 2009: www.derarzneimittelbrief.de\/de\/Artikel.aspx?J=2009&S=89 (accessed 01.03.2025)"},{"issue":"428","key":"3708_CR4","first-page":"981","volume":"10","author":"AL Serra","year":"2014","unstructured":"Serra AL, von Gunten A, Mosimann U, Favrat B (2014) Aptitude \u00e0 la conduite, pathologies psychiatriques et psychotropes chez la personne \u00e2g\u00e9e. Rev Med Suisse 10(428):981\u20135","journal-title":"Rev Med Suisse"},{"issue":"4","key":"3708_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/15389580801895244","volume":"9","author":"SC Marshall","year":"2008","unstructured":"Marshall SC (2008) The role of reduced fitness to drive due to medical impairments in explaining crashes involving older drivers. Traffic Inj Prev 9(4):291\u2013298. https:\/\/doi.org\/10.1080\/15389580801895244","journal-title":"Traffic Inj Prev"},{"key":"3708_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.drugpo.2019.03.006","volume":"68","author":"J Manthey","year":"2019","unstructured":"Manthey J (2019) Cannabis use in europe: current trends and public health concerns. Int J Drug Policy 68:93\u201396. https:\/\/doi.org\/10.1016\/j.drugpo.2019.03.006","journal-title":"Int J Drug Policy"},{"key":"3708_CR7","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(19)31789-1","volume":"394","author":"W Hall","year":"2019","unstructured":"Hall W, Stjepanovi\u0107 D, Caulkins J, Lynskey M, Leung J, Campbell G et al (2019) Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Lancet 394:1580\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(19)31789-1","journal-title":"Lancet"},{"key":"3708_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100227","volume":"10","author":"J Manthey","year":"2021","unstructured":"Manthey J, Freeman TP, Kilian C, L\u00f3pez-Pelayo H, Rehm J (2021) Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates. Lancet Reg Health - Eur 10:100227. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100227","journal-title":"Lancet Reg Health - Eur"},{"key":"3708_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.forsciint.2010.02.014","volume":"198","author":"M-C Senna","year":"2010","unstructured":"Senna M-C, Augsburger M, Aebi B, Briellmann TA, Donz\u00e9 N, Dubugnon J-L et al (2010) First nationwide study on driving under the influence of drugs in Switzerland. Forensic Sci Int 198:11\u20136. https:\/\/doi.org\/10.1016\/j.forsciint.2010.02.014","journal-title":"Forensic Sci Int"},{"key":"3708_CR10","doi-asserted-by":"crossref","unstructured":"Schulze H, Schumacher M, Urmeew R et al DRUID \u2013 Driving under the Influence of Drugs, Alcohol and Medicines, Bundesanstalt f\u00fcr Stra\u00dfenwesen Deutschland 2012","DOI":"10.1093\/eurpub\/ckt126.151"},{"key":"3708_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2018.10.006","volume":"195","author":"MAP Bloomfield","year":"2019","unstructured":"Bloomfield MAP, Hindocha C, Green SF, Wall MB, Lees R, Petrilli K et al (2019) The neuropsychopharmacology of cannabis: a review of human imaging studies. Pharmacol Ther 195:132\u201361. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.10.006","journal-title":"Pharmacol Ther"},{"key":"3708_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/brainsci10110834","volume":"10","author":"M Colizzi","year":"2020","unstructured":"Colizzi M, Bhattacharyya S, Cannabis (2020) Neuropsychiatry and its effects on brain and behavior. Brain Sci 10:834. https:\/\/doi.org\/10.3390\/brainsci10110834","journal-title":"Brain Sci"},{"key":"3708_CR13","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.clinthera.2018.03.013","volume":"40","author":"JP De Aquino","year":"2018","unstructured":"De Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D\u2019Souza DC (2018) The psychiatric consequences of cannabinoids. Clin Ther 40:1448\u201356. https:\/\/doi.org\/10.1016\/j.clinthera.2018.03.013","journal-title":"Clin Ther"},{"key":"3708_CR14","doi-asserted-by":"publisher","first-page":"630247","DOI":"10.3389\/fpsyt.2021.630247","volume":"12","author":"M Sorkhou","year":"2021","unstructured":"Sorkhou M, Bedder RH, George TP (2021) The behavioral sequelae of cannabis use in healthy people: a systematic review. Front Psychiatry 12:630247. https:\/\/doi.org\/10.3389\/fpsyt.2021.630247","journal-title":"Front Psychiatry"},{"key":"3708_CR15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.amepre.2022.07.012","volume":"63","author":"SB Windle","year":"2022","unstructured":"Windle SB, Socha P, Nazif-Munoz JI, Harper S, Nandi A (2022) The impact of cannabis decriminalization and legalization on road safety outcomes: a systematic review. Am J Prev Med 63:1037\u20131052. https:\/\/doi.org\/10.1016\/j.amepre.2022.07.012","journal-title":"Am J Prev Med"},{"key":"3708_CR16","unstructured":"https:\/\/www.bag.admin.ch\/bag\/en\/home\/gesund-leben\/sucht-und-gesundheit\/cannabis\/pilotprojekte.html (accessed 22.07.2025)."},{"key":"3708_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40621-014-0026-z","volume":"1","author":"K Wong","year":"2014","unstructured":"Wong K, Brady JE, Li G (2014) Establishing legal limits for driving under the influence of marijuana. Inj Epidemiol 1:26. https:\/\/doi.org\/10.1186\/s40621-014-0026-z","journal-title":"Inj Epidemiol"},{"issue":"7570","key":"3708_CR18","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/525S2a","volume":"525","author":"J Gould","year":"2015","unstructured":"Gould J (2015) The cannabis crop. Nature 525(7570):S2\u20133. https:\/\/doi.org\/10.1038\/525S2a","journal-title":"Nature"},{"key":"3708_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00414-023-03076-0","volume":"137","author":"L Egloff","year":"2023","unstructured":"Egloff L, Frei P, Gerlach K, Mercer-Chalmers-Bender K, Scheurer E (2023) Effect of vaporizing cannabis rich in Cannabidiol on cannabinoid levels in blood and on driving ability \u2013 a randomized clinical trial. Int J Legal Med 137:1713\u20131723. https:\/\/doi.org\/10.1007\/s00414-023-03076-0","journal-title":"Int J Legal Med"},{"key":"3708_CR20","unstructured":"Ordinance of the FEDRO on the control of the road trafc (Verordnung des ASTRA zur Strassenverkehrskontrollverordnung) Federal Roads Office (Bundesamt f\u00fcr Strassen). https:\/\/www.fedlex.admin.ch (accessed 04.06.2025)"},{"issue":"3","key":"3708_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/1389200043335559","volume":"5","author":"KW Renton","year":"2004","unstructured":"Renton KW (2004) Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5(3):235\u201343. https:\/\/doi.org\/10.2174\/1389200043335559","journal-title":"Curr Drug Metab"},{"key":"3708_CR22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","volume":"14","author":"S Ahmed","year":"2016","unstructured":"Ahmed S, Zhou Z, Zhou J, Chen S-Q (2016) Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinf 14:298\u2013313. https:\/\/doi.org\/10.1016\/j.gpb.2016.03.008","journal-title":"Genomics Proteomics Bioinf"},{"key":"3708_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00228-004-0746-z","volume":"60","author":"TB Bidstrup","year":"2004","unstructured":"Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, Br\u00f8sen K (2004) Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 60:109\u201314. https:\/\/doi.org\/10.1007\/s00228-004-0746-z","journal-title":"Eur J Clin Pharmacol"},{"key":"3708_CR24","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1124\/pr.113.007518","volume":"65","author":"J K\u00f6nig","year":"2013","unstructured":"K\u00f6nig J, M\u00fcller F, Fromm MF (2013) Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 65:944\u2013966. https:\/\/doi.org\/10.1124\/pr.113.007518","journal-title":"Pharmacol Rev"},{"key":"3708_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1146\/annurev.genom.2.1.9","volume":"2","author":"WE Evans","year":"2001","unstructured":"Evans WE, Johnson JA (2001) Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2:9\u201339. https:\/\/doi.org\/10.1146\/annurev.genom.2.1.9","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"3708_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.110822","volume":"323","author":"G Pelletti","year":"2021","unstructured":"Pelletti G, Barone R, Giorgetti A, Garagnani M, Rossi F, Fais P et al (2021) \u201cLight cannabis\u201d consumption in a sample of young adults: preliminary pharmacokinetic data and psychomotor impairment evaluation. Forensic Sci Int 323:110822. https:\/\/doi.org\/10.1016\/j.forsciint.2021.110822","journal-title":"Forensic Sci Int"},{"key":"3708_CR27","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00414-020-02380-3","volume":"134","author":"A Gasse","year":"2020","unstructured":"Gasse A, Vennemann M, K\u00f6hler H, Sch\u00fcrenkamp J (2020) Toxicogenetic analysis of \u22069-THC-metabolizing enzymes. Int J Legal Med 134:2095\u20132103. https:\/\/doi.org\/10.1007\/s00414-020-02380-3","journal-title":"Int J Legal Med"},{"key":"3708_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1124\/dmd.119.086470","volume":"47","author":"GI Patilea-Vrana","year":"2019","unstructured":"Patilea-Vrana GI, Unadkat JD (2019) Quantifying hepatic enzyme kinetics of (-)-\u22069-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in vitro modeling. Drug Metab Dispos 47:743\u201352. https:\/\/doi.org\/10.1124\/dmd.119.086470","journal-title":"Drug Metab Dispos"},{"key":"3708_CR29","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.lfs.2006.12.032","volume":"80","author":"K Watanabe","year":"2007","unstructured":"Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I (2007) Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 80:1415\u20131419. https:\/\/doi.org\/10.1016\/j.lfs.2006.12.032","journal-title":"Life Sci"},{"issue":"3","key":"3708_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/01.ftd.0000211812.27558.6e","volume":"28","author":"HansH. Maurer","year":"2006","unstructured":"Maurer Hans H., Sauer Christoph, Theobald Denis S. (2006) Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of Tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit 28(3):447\u2013453. https:\/\/doi.org\/10.1097\/01.ftd.0000211812.27558.6e","journal-title":"Ther Drug Monit"},{"key":"3708_CR31","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s00414-020-02387-w","volume":"134","author":"C Hassenberg","year":"2020","unstructured":"Hassenberg C, Clausen F, Hoffmann G, Studer A, Sch\u00fcrenkamp J (2020) Investigation of phase II metabolism of 11-hydroxy-\u0394-9-tetrahydrocannabinol and metabolite verification by chemical synthesis of 11-hydroxy-\u0394-9-tetrahydrocannabinol-glucuronide. Int J Legal Med 134:2105\u201319. https:\/\/doi.org\/10.1007\/s00414-020-02387-w","journal-title":"Int J Legal Med"},{"key":"3708_CR32","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/dta.3241","volume":"14","author":"P Frei","year":"2022","unstructured":"Frei P, Frauchiger S, Scheurer E, Mercer-Chalmers\u2010Bender K (2022) Quantitative determination of five cannabinoids in blood and urine by gas chromatography tandem mass spectrometry applying automated on\u2010line solid phase extraction. Drug Test Anal 14:1223\u20131233. https:\/\/doi.org\/10.1002\/dta.3241","journal-title":"Drug Test Anal"},{"key":"3708_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/dta.2114","volume":"9","author":"M H\u00e4dener","year":"2017","unstructured":"H\u00e4dener M, Martin Fabritius M, K\u00f6nig S, Giroud C, Weinmann W (2017) Assessing cannabis consumption frequency: is the combined use of free and glucuronidated THCCOOH blood levels of diagnostic utility? Drug Test Anal 9:1043\u20131051. https:\/\/doi.org\/10.1002\/dta.2114","journal-title":"Drug Test Anal"},{"key":"3708_CR34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/jat\/bkaa046","volume":"44","author":"MA Huestis","year":"2020","unstructured":"Huestis MA, Sempio C, Newmeyer MN, Andersson M, Barnes AJ, Abulseoud OA et al (2020) Free and glucuronide urine cannabinoids after controlled smoked, vaporized and oral cannabis administration in frequent and occasional cannabis users. J Anal Toxicol 44:651\u201360. https:\/\/doi.org\/10.1093\/jat\/bkaa046","journal-title":"J Anal Toxicol"},{"key":"3708_CR35","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1124\/dmd.120.000350","volume":"49","author":"JL Beers","year":"2021","unstructured":"Beers JL, Fu D, Jackson KD (2021) Cytochrome P450\u2013Catalyzed metabolism of Cannabidiol to the active metabolite 7-Hydroxy-Cannabidiol. Drug Metab Dispos 49:882\u2013891. https:\/\/doi.org\/10.1124\/dmd.120.000350","journal-title":"Drug Metab Dispos"},{"key":"3708_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.forsciint.2010.07.011","volume":"203","author":"F Musshoff","year":"2010","unstructured":"Musshoff F, Stamer UM, Madea B (2010) Pharmacogenetics and forensic toxicology. Forensic Sci Int 203:53\u201362. https:\/\/doi.org\/10.1016\/j.forsciint.2010.07.011","journal-title":"Forensic Sci Int"},{"key":"3708_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/toxics9110292","volume":"9","author":"N Di Nunno","year":"2021","unstructured":"Di Nunno N, Esposito M, Argo A, Salerno M, Sessa F (2021) Pharmacogenetics and forensic toxicology: a new step towards a multidisciplinary approach. Toxics 9:292. https:\/\/doi.org\/10.3390\/toxics9110292","journal-title":"Toxics"},{"issue":"2","key":"3708_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/jat\/30.2.65","volume":"30","author":"TC Kupiec","year":"2006","unstructured":"Kupiec TC, Raj V, Vu N (2006) Pharmacogenomics for the forensic toxicologist. J Anal Toxicol 30(2):65\u201372. https:\/\/doi.org\/10.1093\/jat\/30.2.65","journal-title":"J Anal Toxicol"},{"key":"3708_CR39","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41397-020-00195-4","volume":"21","author":"C Jeiziner","year":"2021","unstructured":"Jeiziner C, Suter K, Wernli U, Barbarino JM, Gong L, Whirl-Carrillo M et al (2021) Pharmacogenetic information in Swiss drug labels \u2013 a systematic analysis. Pharmacogenomics J 21:423\u2013434. https:\/\/doi.org\/10.1038\/s41397-020-00195-4","journal-title":"Pharmacogenomics J"},{"key":"3708_CR40","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/jat\/29.7.590","volume":"29","author":"M Jin","year":"2005","unstructured":"Jin M, Gock SB, Jannetto PJ, Jentzen JM, Wong SH (2005) Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol 29:590\u20138. https:\/\/doi.org\/10.1093\/jat\/29.7.590","journal-title":"J Anal Toxicol"},{"key":"3708_CR41","unstructured":"https:\/\/www.pharmgkb.org\/page\/cyp2c9RefMaterials (accessed 04.06.2025)."},{"key":"3708_CR42","unstructured":"https:\/\/www.pharmgkb.org\/page\/cyp2c19RefMaterials (accessed 04.06.2025)."},{"key":"3708_CR43","doi-asserted-by":"publisher","unstructured":"Hans W, Borchers (2023) Pracma: practical numerical math Functions. R package version 2.4.4. https:\/\/doi.org\/10.32614\/CRAN.package.pracma","DOI":"10.32614\/CRAN.package.pracma"},{"key":"3708_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41398-018-0191-x","volume":"8","author":"CJA Morgan","year":"2018","unstructured":"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181. https:\/\/doi.org\/10.1038\/s41398-018-0191-x","journal-title":"Transl Psychiatry"},{"key":"3708_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.drugalcdep.2006.03.015","volume":"85","author":"JG Ramaekers","year":"2006","unstructured":"Ramaekers JG, Moeller MR, Van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G (2006) Cognition and motor control as a function of \u03949-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend 85:114\u201322. https:\/\/doi.org\/10.1016\/j.drugalcdep.2006.03.015","journal-title":"Drug Alcohol Depend"},{"key":"3708_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","volume":"269","author":"N Solowij","year":"2019","unstructured":"Solowij N, Broyd S, Greenwood L, Van Hell H, Martelozzo D, Rueb K et al (2019) A randomised controlled trial of vaporised \u03949-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci 269:17\u201335. https:\/\/doi.org\/10.1007\/s00406-019-00978-2","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3708_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2020.110561","volume":"318","author":"E Gerace","year":"2021","unstructured":"Gerace E, Bakanova SP, Di Corcia D, Salomone A, Vincenti M (2021) Determination of cannabinoids in urine, oral fluid and hair samples after repeated intake of CBD-rich cannabis by smoking. Forensic Sci Int 318:110561. https:\/\/doi.org\/10.1016\/j.forsciint.2020.110561","journal-title":"Forensic Sci Int"},{"key":"3708_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.forsciint.2018.08.009","volume":"291","author":"U Meier","year":"2018","unstructured":"Meier U, Dussy F, Scheurer E, Mercer-Chalmers-Bender K, Hangartner S (2018) Cannabinoid concentrations in blood and urine after smoking cannabidiol joints. Forensic Sci Int 291:62\u201367. https:\/\/doi.org\/10.1016\/j.forsciint.2018.08.009","journal-title":"Forensic Sci Int"},{"key":"3708_CR49","doi-asserted-by":"publisher","first-page":"1055991","DOI":"10.3389\/fphar.2023.1055991","volume":"14","author":"M-E Seo","year":"2023","unstructured":"Seo M-E, Min B-J, Heo N, Lee KH, Kim JH (2023) Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates. Front Pharmacol 14:1055991. https:\/\/doi.org\/10.3389\/fphar.2023.1055991","journal-title":"Front Pharmacol"},{"key":"3708_CR50","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1248\/bpb.b16-00605","volume":"39","author":"M Hiratsuka","year":"2016","unstructured":"Hiratsuka M (2016) Genetic polymorphisms and in Vitro functional characterization of CYP2C8, CYP2C9, and CYP2C19 allelic variants. Biol Pharm Bull 39:1748\u201359. https:\/\/doi.org\/10.1248\/bpb.b16-00605","journal-title":"Biol Pharm Bull"},{"key":"3708_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2133\/dmpk.DMPK-12-RV-085","volume":"28","author":"T Hirota","year":"2013","unstructured":"Hirota T, Eguchi S, Ieiri I (2013) Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 28:28\u201337. https:\/\/doi.org\/10.2133\/dmpk.DMPK-12-RV-085","journal-title":"Drug Metab Pharmacokinet"},{"key":"3708_CR52","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.bcp.2005.07.007","volume":"70","author":"TM Bland","year":"2005","unstructured":"Bland TM, Haining RL, Tracy TS, Callery PS (2005) CYP2C-catalyzed delta (9)-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 70:1096\u20131103. https:\/\/doi.org\/10.1016\/j.bcp.2005.07.007","journal-title":"Biochem Pharmacol"},{"key":"3708_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116191","volume":"228","author":"KCB Yabut","year":"2024","unstructured":"Yabut KCB, Winnie Wen Y, Simon KT, Isoherranen N (2024) CYP2C9, CYP3A and CYP2C19 metabolize \u03949-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1). Biochem Pharmacol 228:116191. https:\/\/doi.org\/10.1016\/j.bcp.2024.116191","journal-title":"Biochem Pharmacol"},{"key":"3708_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/cpt.1830","volume":"108","author":"KN Theken","year":"2020","unstructured":"Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A et al (2020) Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther 108:191\u2013200. https:\/\/doi.org\/10.1002\/cpt.1830","journal-title":"Clin Pharmacol Ther"},{"key":"3708_CR55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103\u2013141. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007","journal-title":"Pharmacol Ther"},{"key":"3708_CR56","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/cpt.3378","volume":"116","author":"K Abouir","year":"2024","unstructured":"Abouir K, Exquis N, Gloor Y, Daali Y, Samer CF (2024) Phenoconversion due to drug\u2013drug interactions in CYP2C19 genotyped healthy volunteers. Clin Pharmacol Ther 116:1121\u20131129. https:\/\/doi.org\/10.1002\/cpt.3378","journal-title":"Clin Pharmacol Ther"},{"key":"3708_CR57","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1111\/bcp.15349","volume":"88","author":"KE Kvitne","year":"2022","unstructured":"Kvitne KE, Krogstad V, Wegler C, Johnson LK, Kringen MK, Hovd MH et al (2022) Short- and long\u2010term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity. Br J Clin Pharmacol 88:4121\u201333. https:\/\/doi.org\/10.1111\/bcp.15349","journal-title":"Br J Clin Pharmacol"},{"key":"3708_CR58","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1124\/dmd.121.000442","volume":"49","author":"S Nasrin","year":"2021","unstructured":"Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P (2021) Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metab Dispos 49:1070\u20131080. https:\/\/doi.org\/10.1124\/dmd.121.000442","journal-title":"Drug Metab Dispos"},{"key":"3708_CR59","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/ph14050487","volume":"14","author":"M Hahn","year":"2021","unstructured":"Hahn M, Roll SC (2021) The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug\u2013drug interactions: drug\u2013gene, drug\u2013gene\u2013gene and drug\u2013drug\u2013gene interactions. Pharmaceuticals 14:487. https:\/\/doi.org\/10.3390\/ph14050487","journal-title":"Pharmaceuticals"},{"key":"3708_CR60","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s40264-020-00983-8","volume":"43","author":"V Rollason","year":"2020","unstructured":"Rollason V, Mouterde M, Daali Y, \u010c\u00ed\u017ekov\u00e1 M, Priehodov\u00e1 E, Kulichov\u00e1 I et al (2020) Safety of the Geneva cocktail, a cytochrome P450 and P-Glycoprotein phenotyping cocktail, in healthy volunteers from three different geographic origins. Drug Saf 43:1181\u20131189. https:\/\/doi.org\/10.1007\/s40264-020-00983-8","journal-title":"Drug Saf"},{"key":"3708_CR61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40262-015-0294-y","volume":"55","author":"A Derungs","year":"2016","unstructured":"Derungs A, Donzelli M, Berger B, Noppen C, Kr\u00e4henb\u00fchl S, Haschke M (2016) Effects of cytochrome P450 inhibition and induction on the phenotyping metrics of the Basel cocktail: a randomized crossover study. Clin Pharmacokinet 55:79\u201391. https:\/\/doi.org\/10.1007\/s40262-015-0294-y","journal-title":"Clin Pharmacokinet"},{"key":"3708_CR62","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/clpt.2008.213","volume":"85","author":"C Sachse-Seeboth","year":"2009","unstructured":"Sachse-Seeboth C, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E et al (2009) Interindividual variation in the pharmacokinetics of \u03949-Tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 85:273\u20136. https:\/\/doi.org\/10.1038\/clpt.2008.213","journal-title":"Clin Pharmacol Ther"},{"key":"3708_CR63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrn3475","volume":"14","author":"KS Button","year":"2013","unstructured":"Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ et al (2013) Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 14:365\u2013376. https:\/\/doi.org\/10.1038\/nrn3475","journal-title":"Nat Rev Neurosci"},{"key":"3708_CR64","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/cbdv.200790152","volume":"4","author":"MA Huestis","year":"2007","unstructured":"Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4:1770\u20131804. https:\/\/doi.org\/10.1002\/cbdv.200790152","journal-title":"Chem Biodivers"},{"key":"3708_CR65","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"CJ Lucas","year":"2018","unstructured":"Lucas CJ, Galettis P, Schneider J (2018) The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 84:2477\u20132482. https:\/\/doi.org\/10.1111\/bcp.13710","journal-title":"Br J Clin Pharmacol"},{"key":"3708_CR66","doi-asserted-by":"publisher","first-page":"9449","DOI":"10.1007\/s00216-013-7381-4","volume":"405","author":"G Skopp","year":"2013","unstructured":"Skopp G, Mikus G (2013) An in vitro experiment on the interaction of charcoal or wheat bran with 11-nor-9-carboxy-\u22069-tetrahydrocannabinol and its glucuronide. Anal Bioanal Chem 405:9449\u20139453. https:\/\/doi.org\/10.1007\/s00216-013-7381-4","journal-title":"Anal Bioanal Chem"},{"key":"3708_CR67","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.forsciint.2012.08.013","volume":"223","author":"M Fabritius","year":"2012","unstructured":"Fabritius M, Staub C, Mangin P, Giroud C (2012) Distribution of free and conjugated cannabinoids in human bile samples. Forensic Sci Int 223:114\u2013118. https:\/\/doi.org\/10.1016\/j.forsciint.2012.08.013","journal-title":"Forensic Sci Int"},{"key":"3708_CR68","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00414-018-1919-0","volume":"133","author":"JS Schneider","year":"2019","unstructured":"Schneider JS, Gasse A, Sch\u00fcrenkamp M, Sibbing U, Banken S, Pfeiffer H et al (2019) Multiplex analysis of genetic polymorphisms within UGT1A9, a gene involved in phase II of \u03949-THC metabolism. Int J Legal Med 133:365\u201372. https:\/\/doi.org\/10.1007\/s00414-018-1919-0","journal-title":"Int J Legal Med"}],"container-title":["International Journal of Legal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00414-025-03708-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00414-025-03708-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00414-025-03708-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:35:32Z","timestamp":1778474132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00414-025-03708-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3708"],"URL":"https:\/\/doi.org\/10.1007\/s00414-025-03708-7","relation":{},"ISSN":["0937-9827","1437-1596"],"issn-type":[{"value":"0937-9827","type":"print"},{"value":"1437-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The original study [\n                      \n                      ] was approved by the ethics committee northwest\/central Switzerland (Ethikkommission Nordwest- und Zentralschweiz, EKNZ, BASEC-ID: 2019 \u2212 00639) and conducted with the ethical standards in accordance with the Declaration of Helsinki at the Institute of Forensic Medicine of the University of Basel. Written informed consent was obtained from all individual participants included in the original study [\n                      \n                      ]. Participants who agreed to a further use of their biological samples and data gave explicitly their written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval\u00a0<!--Emphasis Type='Bold' removed-->and informed participant consent"}},{"value":"The original clinical trial was registered with the German Clinical Trials Register (DRKS00018836) and with the Coordination Office for Human Research (kofam) which is operated by the Federal Office of Public Health (FOPH) (SNCTP000003294) [","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Clinical trial number"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}